AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AxoGen, Inc.NASDAQ: AXGN

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 74.8%

Gross margin was 74.8% in Q3 FY2026, down 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 74.2%, down 0.6 pp year over year. Over 3 fiscal years it narrowed by 4.2 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
74.8%+2.1 pp QoQ
Last fiscal yearDec 2025
74.3%-1.5 pp YoY
LTMSep 2026
74.2%-0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.7 pp——
1 year-1.5 pp——
3 years-4.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
74.3%
Year-over-year change
-1.5pp

Gross Margin vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's LTM Sep 2026 gross margin of 74.2% is the 3rd highest of the 7 companies compared; the peer median is 69.1%.
  • Its year-over-year change of -0.6 pp is the 4th highest of 7, against a peer median of -0.2 pp.
  • Over three fiscal years its change of -4.2 pp compares with a peer median of +1.5 pp.
AXGN Competitors Peer median
Gross Margin for AXGN and competitors
Company Period LTM level YoY 3-year change
BSEMBioStem Technologies, Inc.LTM Jun 2026112.8% +15.8 pp+6.0 pp
MDXGMiMedx Group, Inc.LTM Mar 202681.0% -0.8 pp+0.6 pp
AXGNAxoGen, Inc.LTM Sep 202674.2% -0.6 pp-4.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
TELATELA Bio, Inc.LTM Jun 202667.8% +0.5 pp+2.4 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 202662.3% +4.2 pp+7.5 pp
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
Peer median (excluding AXGN) 69.1%-0.2 pp+1.5 pp

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.36M138.58M159.01M187.34M225.21M
Cost of Revenue22.93M29.78M37.14M45.36M57.86M
Gross Profit104.43M108.81M121.87M141.98M167.35M
Gross Margin82.0%78.5%76.6%75.8%74.3%
Research & Development24.18M25.63M27.34M27.77M32.89M
Selling, General & Admin105.67M112.89M115.99M117.5M142.32M
Operating Expenses129.84M138.52M143.33M145.26M175.2M
Depreciation & Amortization4.74M4.85M5.55M7.84M8.19M
EBITDA(20.89M)(23.47M)(13.33M)6.08M192K
EBITDA Margin-16.4%-16.9%-8.4%3.2%0.1%
Operating Income(25.42M)(29.71M)(21.46M)(3.29M)(7.85M)
Operating Margin-20.0%-21.4%-13.5%-1.8%-3.5%
Interest Income00000
Interest Expense1.36M624K2.84M8.21M7.7M
Other Income / Expenses(1.57M)759K(254K)(6.68M)(7.85M)
Income Before Tax(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Pre-Tax Margin-21.2%-20.9%-13.7%-5.3%-7.0%
Income Tax Expense00000
Net Income(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Net Margin-21.2%-20.9%-13.7%-5.3%-7.0%
EPS (Basic)(0.65)(0.69)(0.51)(0.23)(0.34)
EPS (Diluted)(0.65)(0.69)(0.51)(0.23)(0.34)
Weighted Avg Shares41.22M42.08M42.88M44.26M46.05M
Weighted Avg Shares (Diluted)41.22M42.08M42.88M44.26M46.05M

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.